In GBM for instance, Nuclear Factor-κB (NF-κB) activation, which correlates with poor patient prognosis, promotes mesenchymal differentiation and therapeutic resistance as shown by several groups including our own2,4. The gene discussed is NFKB1; the disease is glioblastoma.